The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
||||||||||||||||
| COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
| VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
| NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
| Progenity Inc. | COM | 74319F107 | 97,535 | 20,490,566 | SH | SOLE | NA | 20,490,566 | 0 | 0 | |
| Progenity Inc. | COM | 74319F107 | 31,135 | 6,541,060 | SH | OTR | NA | 0 | 6,541,060 | 0 | |
| Amryt Pharma PLC | Sponsored ADS | 03217L106 | 62,964 | 4,520,000 | SH | SOLE | NA | 4,520,000 | 0 | 0 | |
| Recro Pharma Inc. | Com | 75629F109 | 6,145 | 2,202,420 | SH | SOLE | NA | 2,202,420 | 0 | 0 | |